Literature DB >> 11240803

Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study.

J. Belinson1, Y. Qiao, R. Pretorius, W. Zhang, K. Keaton, P. Elson, C. Fischer, A. Lorincz, D. Zahniser, D. Wilbur, Q. Pan, L. Li, C. Biscotti, A. Dawson, A. Li, L. Wu, Y. Ling, C. P. Ma, X. P. Yang.   

Abstract

For cervical cancer screening to be feasible in developing countries, it must be accurate, inexpensive, and easy to administer. We conducted a pilot study in rural Shanxi Province, People's Republic of China, to determine disease prevalence and study feasibility in preparation for a large-scale comparative trial of 6 screening tests. One-hundred and thirty-six nonpregnant women with no history of hysterectomy, pelvic radiation, or Papanicolaou tests were screened in a rural clinic. Ten percent of the women enrolled reported abnormal vaginal bleeding and 45% reported abnormal vaginal discharge. The tests were the Papanicolaou test (both conventional and ThinPrep), a self-administered swab test by Hybrid Capture II for high-risk human papillomavirus (HPV), a test for high-risk HPV from residual PreservCyt medium, fluorescence spectroscopy, and visual inspection of the cervix by a clinician. All women also underwent colposcopy and biopsies as the reference standard. Biopsies showed 12 of 136 women had >/= high-grade squamous intraepithelial lesions (HGSIL). Screening was completed in 5 half-day sessions, the procedures went smoothly, and local cooperation was enthusiastic. Disease prevalence in Xiangyuan and Yangcheng Counties, Shanxi Province, can be estimated at 8.8% (95% CI, 4.5% to 15.0%). Screening 1000-2000 patients would be sufficient to detect a 10% difference in accuracy between diagnostic tests. The proposed large-scale trial is feasible.

Entities:  

Year:  1999        PMID: 11240803     DOI: 10.1046/j.1525-1438.1999.99055.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Comparative community outreach to increase cervical cancer screening in the Mississippi Delta.

Authors:  Philip E Castle; Alfio Rausa; Tameka Walls; Patti E Gravitt; Edward E Partridge; Vanessa Olivo; Shelley Niwa; Kerry Grace Morrissey; Laura Tucker; Hormuzd Katki; Isabel Scarinci
Journal:  Prev Med       Date:  2011-04-08       Impact factor: 4.018

Review 2.  Human papillomavirus in cervical cancer.

Authors:  F Xavier Bosch; Silvia de Sanjosé
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

3.  Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis.

Authors:  G S Ogilvie; D M Patrick; M Schulzer; J W Sellors; M Petric; K Chambers; R White; J M FitzGerald
Journal:  Sex Transm Infect       Date:  2005-06       Impact factor: 3.519

4.  Systems analysis of real-world obstacles to successful cervical cancer prevention in developing countries.

Authors:  Eric J Suba; Sean K Murphy; Amber D Donnelly; Lisa M Furia; My Linh D Huynh; Stephen S Raab
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

5.  Factors affecting the detection rate of human papillomavirus.

Authors:  Diane M Harper; Meghan R Longacre; Walter W Noll; Dorothy R Belloni; Bernard F Cole
Journal:  Ann Fam Med       Date:  2003 Nov-Dec       Impact factor: 5.166

6.  The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women.

Authors:  G Bigras; F de Marval
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

7.  Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.

Authors:  Rong Wang; Xiao-Lei Guo; G Bea A Wisman; Ed Schuuring; Wen-Feng Wang; Zheng-Yu Zeng; Hong Zhu; Shang-Wei Wu
Journal:  BMC Infect Dis       Date:  2015-07-04       Impact factor: 3.090

8.  Cancer of the Uterine Cervix.

Authors:  Eliane Duarte-Franco; Eduardo L Franco
Journal:  BMC Womens Health       Date:  2004-08-25       Impact factor: 2.809

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.